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Abstract
Background: The widespread use of the Medical Outcomes Study (MOS) 36-item Short-Form Health
Survey (SF-36) facilitates the comparison of health-related quality of life (HRQL) across independent
studies. Objectives: To compare the scores of eight scales and two summary scales of the SF-36 across
participants in the Women’s Healthy Eating and Living (WHEL) trial, the Women’s Health Initiative-
Dietary Modification trial (WHI-DM), and the MOS, and to illustrate the use of effect sizes for interpreting
the importance of group differences. Methods: WHEL and WHI-DM are both multi-center dietary inter-
ventions; only data from the UC Davis sites were used in our study. WHEL participants had a recent
history of breast cancer, WHI-DM participants were healthy, postmenopausal women, and women in the
MOS had a history of hypertension, diabetes, heart disease, or depression. General linear models were used
to identify statistically significant differences in scale scores. Meaningful differences were determined by
effect sizes computed using a common within-group standard deviation (SD) and SDs from normative data.
Results: After adjusting for age and marital status, SF-36 scores for the WHI-DM and WHEL samples
were similar and both had statistically significantly higher scores than the MOS sample. Relative to the
WHEL or WHI-DM studies, MOS scores for scales related to the physical domain were clearly mean-
ingfully lower whereas scale scores related to the mental health domain were potentially meaningfully
lower. Conclusions: The HRQL of breast cancer survivors is comparable to that of healthy women and
better than that of women with chronic health conditions, particularly with respect to physical health. This
study illustrated the use of ranges of effects sizes for aiding the interpretation of SF-36 scores differences
across independent studies.
Key words: Breast cancer, Effect sizes, Meaningful difference, Quality of life, SF-36
Abbreviations: ANCOVA – analysis of covariance; HRQL – health-related quality of life; MANCOVA –
multivariate analysis of covariance; MCS – mental component summary scale; MOS – Medical Outcomes
Study; PCS – physical component summary scale; SF-36 – 36-item short-form health survey; SD – standard
deviation; WHEL – Women’s Healthy Eating and Living trial; WHI-DM – Women’s Health Initiative-
Dietary Modification trial
Introduction
The Medical Outcomes Study (MOS) was aimed
at evaluating the effects of cost containment on
patient outcomes [1]. The most renowned outcome
measurement instrument to emerge from the MOS
was the 36-item short form (SF-36) health survey,
which was developed to assess the physical and
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mental health components of general health status
in individuals with chronic conditions (i.e.,
hypertension, diabetes, heart disease, and depres-
sion) [2, 3]. The SF-36 measures eight health
concepts: physical functioning, role limitations due
to physical problems (role-physical), bodily pain,
general health perceptions, vitality, social func-
tioning, role limitations due to emotional prob-
lems (role-emotional), and mental health [3].
Scores for these eight scales can be combined into
two summary scales: the physical component
summary scale (PCS) and the mental component
summary scale (MCS) [4]. The physical function-
ing, role-physical and bodily pain scales have a
strong association with the physical health com-
ponent, and the mental health, role-emotional and
social functioning scales have a strong association
with the mental health component. Vitality and
general health are moderately associated with both
the physical and mental health components, and
social functioning is also moderately associated
with physical health [3].
Despite being designed to assess general health
status, the SF-36 has often been interpreted as a
measure of health-related quality of life (HRQL)
[3]. Because of its popularity and acceptance as a
measure of HRQL, the SF-36 has been adminis-
tered to a variety of individuals, including samples
from the general population [3], disadvantaged
elderly [5], and people with particular health con-
ditions, including cancer [6–8].
The widespread use of the SF-36 facilitates
comparisons of results across different groups of
individuals. Ganz et al. [9] found that breast can-
cer survivors who were assessed 2 and 3 years post-
diagnosis scored higher (i.e., better HRQL) on all
SF-36 scales when compared to participants in the
MOS longitudinal study. However, the statistical
and clinical significance of these differences were
not discussed. Anderson et al. [6] compared SF-36
scores of AIDS patients to those of patients with
cancer or other serious illnesses. Patients with
cancer or other illnesses consistently scored sig-
nificantly higher than AIDS patients on social
functioning, role-emotional, and vitality. Baseline
bodily pain scores were significantly higher (less
pain) for cancer patients compared to AIDS
patients (p = 0.024), but the difference was only
3.0 points on a scale ranging from 0 to 100 [6],
which is unlikely to be clinically or socially
meaningful [3]. In a secondary analysis of patients
with 13 different health conditions, Sprangers
et al. [8] found that cancer patients ranked sixth
overall in their SF-36 scores. That is, patients
from five other illness groups, including those
with cardiovascular conditions, scored higher than
cancer patients, whereas seven patient groups,
including those with chronic respiratory diseases,
scored lower [8]. Sprangers et al. used a difference
in group means of 2 points on a scale of 0 to 100
to identify meaningful group differences, although
they acknowledge that this criterion was not based
on empirical evidence.
These examples illustrate several points. First,
the widespread use of the SF-36 facilitates com-
parisons of HRQL across patient groups. Second,
the HRQL of cancer patients and survivors, as
measured by the SF-36, is fairly good relative to
patients with other chronic illnesses. Third, com-
parisons of SF-36 scores across groups are limited
in that the magnitude of group differences are not
interpreted at all, or interpretation relied on sta-
tistical significance and unsubstantiated criteria.
We were interested in capitalizing on the wide-
spread use of the SF-36 to compare existing
HRQL data for three distinct groups of women
with different health profiles: (1) women with a
recent history of breast cancer, (2) post-meno-
pausal women without a history of breast or
colorectal cancer or heart disease, and (3) women
with a history of hypertension, heart disease, dia-
betes, or depression. The objectives of our study
were to compare baseline scores for the eight SF-
36 scales and two summary scales for three sam-
ples of women with different health profiles, and to
illustrate the use of effect sizes for interpreting the
importance of group differences.
Methods
Study participants
We performed a secondary analysis of baseline SF-
36 data for three groups of women: participants at
the University of California at Davis (UC Davis)
site of the Women’s Healthy Eating and Living
trial (WHEL), participants at the UC Davis site of
the Women’s Health Initiative-Dietary Modifica-
tion trial (WHI-DM), and female participants in
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the MOS. WHEL is a multi-center, randomized
dietary intervention trial of women diagnosed and
treated for breast cancer [Stage I (P 1 cm), II, or
IIIA] within four years of enrollment to the study
and between the ages of 18 and 70 years at
diagnosis [10]. WHEL was designed to determine
the effects of a low fat, high fiber diet on
breast cancer recurrence and disease-free survival
[11]. The intervention group of the WHEL
study reduced their daily calories from fat to
15–20% and consumed daily 5 servings of vege-
tables, 16 ounces of vegetable juice, 3 servings of
fruit, and 30 grams of fiber. The control arm
followed the National Cancer Institute’s
‘‘5-A-Day’’ program, which recommends eat-
ing five servings of fruits and vegetables each day
[11].
The WHI is another multi-center study of wo-
men that has several clinical trials and an obser-
vational study [12]. In the dietary modification
arm of the clinical trial (WHI-DM), post-meno-
pausal women were randomized to a dietary
intervention to determine the effects of a low fat
diet on the incidence of breast cancer, colorectal
cancer, and heart disease [12, 13]; thus, women
were ineligible if they had a history of these dis-
eases. WHI-DM participants were between 50 and
79 years of age at baseline. The intervention group
reduced total fat intake to 20% and saturated fat
to less than 7% of daily calories, and the control
group had no dietary modification [12, 13]. Only
the UC Davis site of the WHI-DM was included in
our study.
The MOS had both cross-sectional and longi-
tudinal components, and it included men and
women aged 18–98 years living in Boston, Chi-
cago, or Los Angeles who had prevalent and
treatable chronic conditions particularly, hyper-
tension, heart disease, diabetes, and/or depression
[14]. Persons with a history of any cancer (except
skin cancer) within the past 3 years were excluded
from the longitudinal component [15]. Methods
for sampling patients for the longitudinal compo-
nent of the MOS are described in detail elsewhere
[15]. The SF-36 was administered to 3588 partici-
pants in the longitudinal component of the MOS
[14], which measured change in chronic conditions
over time and evaluated outcomes with respect to
systems of care, provider specialty, and styles of
practice.
At the time this secondary data analysis was
initiated, baseline SF-36 data were available for
427 women enrolled at the UC Davis WHEL site.
Over 500 women were eventually enrolled at that
site. Baseline SF-36 data were obtained for 791
women randomized to the dietary modification
trial at the UC Davis WHI-DM site. Recruitment
for WHI-DM began in 1993 and was completed at
the time of our study. Information on study design
and participant recruitment are presented else-
where for the WHI-DM [12, 13] and WHEL [11].
Data from the MOS longitudinal study (Radius
data set #30–34) were purchased from Sociometric
Corporation and included baseline SF-36 data.
Only the 2,180 female MOS participants in the
longitudinal component of the MOS were included
in our study.
Participants who were missing data for one or
more SF-36 scales or for the demographic vari-
ables age, education, marital status and race were
excluded as these individuals would not contribute
information to the analyses. For WHEL partici-
pants, 420 (98.4%) women had complete data.
Complete data were available for 764 (96.6%)
WHI-DM participants, and for 1741 (79.9%) of
the female MOS participants.
During preliminary analyses, we conducted tests
for homogeneity of variances (Levene test and
Brown & Forsythe test, SAS PROC GLM,
HOVTEST option [16]). The tests were statistically
significant for all scales (all p < 0.001 except for
vitality where p < 0.01 and bodily pain where
p < 0.05) indicating variances were not equal
across the three studies. When the sample sizes of
each group are equal, statistical tests are robust to
violations in the assumption of homogeneity of
variance across groups for an analysis of variance
(ANOVA) [16, 17] and to violations in the
assumption of homogeneity of variance–covari-
ance matrices for a multivariate analysis of vari-
ance (MANOVA) [18]. To safeguard against the
heteroscedasticity in our data, all samples were
limited to the size of the smallest group, which was
the WHEL sample. Samples of similar size
(n ¼ 420) were selected from the WHI-DM and
MOS studies using simple random sampling
without replacement. We evaluated the represen-
tativeness of the random samples by comparing
SF-36 scores (median, 1st and 3rd quartile,
mean, standard deviation) and demographic
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characteristics of the WHI-DM and MOS samples
(n ¼ 420 each) to scores and characteristics of
their respective sampling frames (i.e., n ¼ 764
WHI-DM or n ¼ 1741 MOS participants). Be-
cause the samples and sampling frames were not
independent, formal statistical tests were not con-
ducted to assess representativeness.
Scale scores
The SF-36 scoring algorithms were used to com-
pute scores for the eight scales [3] and the two
summary measures [4]. Although the WHI-DM
[19] and WHEL studies use the RAND-36 scoring
algorithms, we used the SF-36 algorithms to facil-
itate comparisons with population normative data.
A scale was considered missing if greater than 50%
of the items comprising the scale were missing [3]. If
50% or less of the items were missing, the scale was
calculated as the average of the observed items.
This approach has been shown to be an acceptable
method of imputing missing data for other HRQL
instruments when at least 50% of items comprising
a scale are observed [20]. Individuals with missing
scale scores for any of the eight scales were ex-
cluded. Scale scores range from 0 to 100, with
higher scores representing better HRQL.
The bodily pain scale consists of two items. One
of these items, measuring severity of pain during
the past 4 weeks (BP1), has six response options
ranging from 1 ¼ ‘none’ to 6 ¼ ‘very severe’.
However, this item was incorrectly typed on the
questionnaire administered to WHI-DM and
WHEL participants in that only five response
options were provided (the ‘very severe’ option
was inadvertently omitted). For these two studies,
BP1 was scored the same way as the second bodily
pain item (BP2), which addresses pain interfering
with normal work and has a 5-category response
scale. Specifically, BP1 was scored as follows:
‘none’ ¼ 6, ‘very mild’ ¼ 4.75, ‘mild’ ¼ 3.5,
‘moderate’ ¼ 2.25 and ‘severe’ ¼ 1. Other than
this minor deviation, the scoring algorithms were
followed as prescribed by the developers of the SF-
36 to convert the two items into the bodily pain
scale with possible scores ranging from 0 to 100 [3,
4]. PCS and MCS scores were calculated as
weighted linear combinations of the eight stan-
dardized SF-36 scales, where the weights were
based on factor loadings from a principal com-
ponent analysis [4]. In the general population, PCS
and MCS have mean scores of 50 and SDs of 10,
with higher scores representing better physical and
mental health [4].
Data analysis
Multivariate analysis of covariance (MANCOVA,
SAS PROC GLM [21]) was used to compare the
eight SF-36 scale scores across the WHI-DM,
WHEL, and MOS studies. The SF-36 scores were
the dependent variables and study (WHI-DM,
WHEL, MOS) was the independent variable. Be-
cause the PCS and MCS are linear combinations
of the eight SF-36 scales, they were assessed in a
separate MANCOVA. Numerous studies have
shown that HRQL varies by demographic char-
acteristics [22–26]; therefore, the covariates age,
education (6high school vs. > high school),
marital status (married or living as married vs.
other), and race (white vs. non-white) were as-
sessed for statistical significance, which was de-
fined as Wilks’ Lambda p < 0.05. If the null
hypothesis (i.e., the vectors of average scale scores
for all three groups were the same) was rejected,
separate ANCOVAs were used to identify the
individual scales on which the groups differed
significantly. Post hoc analyses were performed to
determine which groups contributed to the signif-
icant differences in the ANCOVA and to estimate
least squares adjusted mean score differences
among the three studies. Significance levels for the
post hoc analyses were adjusted using Tukey’s
Honestly Significant Difference, with the experi-
ment-wise error held at a = 0.05. Least squares
adjusted mean score differences were computed as
the mean difference in SF-36 scores between
studies evaluated at the mean of each of the co-
variates in the model.
Identifying meaningful differences
In the present study, we used effect sizes to assess
the meaningfulness of group differences in SF-36
scale scores. Effect sizes have been widely used for
the purpose of interpreting HRQL score differ-
ences [27–31]. The effect size of a mean difference
was calculated by dividing the difference in group
means by a reference SD; effect size =
ðX1  X2=SD [32, 33]. We employed two sources
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for the SD. The first was the root mean square
error (RMSE) for each scale or summary scale
from the ANCOVA, which is an estimate of the
common within-group SD. The second source was
an external reference population; the general U.S.
population SD for women [3]. Cohen provides
guidelines for interpreting effect sizes where 0.2 is
‘small’, 0.5 is ‘medium’, and 0.8 is ‘large’ [33]. For
our purposes, we defined group differences as very
small and clearly not meaningful if they were
associated with effect sizes less than 0.2. Group
differences with effect sizes greater than 0.5 were
considered clearly meaningful [31], and differences




Table 1 provides information on the characteris-
tics of the WHEL, WHI-DM, and MOS samples.
Random samples of 420 WHI-DM and 420 MOS
participants were representative of their sampling
frames with the following exceptions. The WHI-
DM sample had slightly fewer married (66.2% vs.
68.2%) and more highly educated (post-high
school 85.5% vs. 83.3%) women than the sam-
pling frame of 764 women. The MOS sample had
slightly lower mean role-emotional scores (62.8 vs.
65.7) and slightly higher mean general health
scores (62.0 vs. 60.1) than the sampling frame of
1741 women. All other mean scores for the MOS
sample differed by approximately 1 point or less
from those of the sampling frame.
The three samples differed significantly with re-
spect to age, race, marital status and education (all
p < 0.001). The MOS sample had the youngest
mean age and broadest age range. The samples
were predominantly white, but the MOS study had
a higher proportion of non-white participants.
WHEL and WHI-DM participants were more
likely to be married and have a post-high school
education than MOS participants.
Figure 1 compares average crude (unadjusted)
SF-36 scale scores for the three samples and nor-
mative data for females from the general U.S.
population (n ¼ 1412) [3]. The eight scales are or-
dered on this figure from left to right based on the
degree to which they measure physical or mental
health [3]. WHEL,WHI-DM and norm scores were
similar and higher than those for the MOS. There
was no clear pattern to suggest that group differ-
ences between scales on the left side of the figure that
are more closely related to physical health were
consistently larger or smaller than differences be-
tween scales on the right side of the figure that are
more closely related to mental health.
General linear models
The MANCOVA revealed overall differences in
the eight SF-36 scales (p < 0.001) and two sum-
mary scales (p < 0.001) across the WHEL, WHI-
DM, and MOS samples. The covariates age and
marital status were statistically significant in the
MANCOVA for SF-36 scales and summary scales,
but race and education were not significant in ei-
ther analysis. ANCOVAs were conducted for each
scale and summary scale and included the covari-
ates age and marital status. Results of the AN-
COVA indicated that the three studies differed
significantly in their scores for scales and summary
scales; all p < 0.001 except for bodily pain
(p ¼ 0.32).
Adjusted mean differences for the eight scales,
MCS, and PCS were estimated and are presented
in Table 2. Because the mean differences were
adjusted for age, we decided to use the age-specific




















Figure 1. Comparison of SF-36 scores for WHEL, WHI-DM,
MOS studies and General U.S. Population Norms for Fema-
les.WHEL: Women’s Healthy Eating and Living Study WHI-
DM: Women’s Health Initiative-Dietary Modification trial
MOS: Medical Outcomes Study PF: physical functioning, RP:
role-physical, BP: bodily pain, GH: general health, VT: vitality,
SF: social functioning, RE: role-emotional, MH: mental health.
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women combined to compute standardized effect
sizes, which allowed us to derive a range of plau-
sible standardized effects sizes to aid the interpre-
tation of group differenced. RMSEs were similar
to age-specific population norm SDs, although
they tended to be on the lower end of the ranges.
Effect sizes computed using the RMSE were also
comparable to those computed using the popula-
tion norm SDs. Scale score difference between the
WHI-DM sample compared to the WHEL sample
were very similar and statistically significant only
for the role-physical and general health scales;
however, these differences were no longer signifi-
cant after adjusting for multiple comparisons. Ef-
fect sizes for the WHI-DM vs. WHEL differences
were all less than 0.20 and clearly not meaningful.
Average scores for the MOS samples were signifi-
cantly lower than scores for the WHI-DM and
WHEL samples for all scales except bodily pain.
The largest differences in adjusted scale scores
were for role-physical and role-emotional, and
scores were the most similar for bodily pain and
mental health (Table 2). Differences between the
WHI-DM and MOS studies and between the
WHEL and MOS studies were statistically signif-
icant and clearly meaningful (effect sizes > 0.5) for
physical functioning, role-physical, general health,
role-emotional and PCS, whereas the statistically
significant score differences for vitality, social
functioning, mental health and MCS were poten-
tially meaningful.
Discussion
WHI-DM participants had comparable HRQL to
WHEL participants and both samples had better
HRQL than MOS participants. Adjusting for age
and marital status tended to decrease the magni-
tude of the differences between groups. WHEL
participants had a recent history of Stage I, II, or
IIIA breast cancer, the treatment of which involves
one or more of the following: surgery, radiation
therapy, chemotherapy, and hormone therapy







Age [mean (SD)] 53.9 (8.8) 62.8 (6.8) 52.5 (16.0)
Age [n (%)]
<45 63 (15.0) 0 (0) 143 (34.1)
45–54 187 (44.5) 50 (11.9) 78 (18.6)
55–64 111 (26.4) 194 (46.2) 80 (19.1)
65–74 59 (14.1) 157 (37.4) 93 (22.1)
75+ 0 (0) 19 (4.5) 26 (6.2)
Race/ethnicity [n (%)]
White 372 (88.6) 372 (88.6) 323 (76.9)
Black 5 (1.2) 12 (2.9) 71 (16.9)
Hispanic 14 (3.3) 13 (3.1) 11 (2.6)
Other 29 (6.9) 23 (5.5) 15 (3.6)
Marital status [n (%)]
Married/living as married 311 (74.1) 278 (66.2) 214 (51.0)
Single/never married 35 (8.3) 7 (1.7) 61 (14.5)
Divorced/separated 53 (12.6) 65 (15.5) 75 (17.9)
Widowed 21 (5.0) 70 (16.7) 70 (16.7)
Education [n (%)]
Less than high school 4 (1.0) 8 (1.9) 51 (12. 1)
High school/GED 57 (13.6) 54 (12.9) 137 (32.6)
Post HS training/some college 181 (43.1) 221 (52.6) 135 (32.1)
College degree or higher 178 (42.4) 137 (32.6) 97 (23.1)
MOS: Medical Outcomes Study
WHEL: Women’s Healthy Eating and Living Study
WHI-DM: Women’s Health Initiative-Dietary Modification trial
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(e.g., Tamoxifen). Because of these treatments, one
might expect the HRQL of these women to be
lower than that of women in the general popula-
tion or women without a history of cancer. Al-
though the HRQL of women with breast cancer
declines during treatment, it improves during the
first year after diagnosis and fluctuates only
slightly 2 and 3 years after diagnosis [9, 34]. Hel-
geson et al. assessed the trajectories of change in
PCS and MCS scores from 4 to 55 months after
breast cancer diagnosis and found that scores for
the majority of women either stayed roughly the
same or improved slightly over that time period
[35]. Only 2.1% of women exhibited a decreasing
trend in PCS, and 12.2% of women had a
decreasing trend in MCS scores [35]. The average
time from breast cancer diagnosis to enrollment in
the WHEL study was approximately 2 years;
therefore, HRQL for the majority of women in the
WHEL sample may have recovered (i.e., ap-
proached or even surpassed pre-cancer HRQL
levels) by the time they were enrolled. Further-
more, breast cancer survivors often report better
HRQL than the general population [9, 36, 37].
The similarity in HRQL among the WHEL and
WHI-DM studies may also be due in part to
similarities in sample characteristics. WHEL and
WHI-DM participants in our study live in roughly
the same area of northern California, both studies
are dietary interventions, participants have similar
educational and race/ethnic backgrounds, and
participants in both studies are highly motivated.
However, the lack of statistically significant and
meaningful differences between the WHI-DM and
WHEL studies may be due to the general nature of
the SF-36 instrument, which may not be sensitive
to subtle differences in HRQL due to breast cancer
diagnosis and treatment. For example, arm pain,
sexual functioning, body image and fear of recur-
rence are not measured on the SF-36. These have
been shown to be related to HRQL in breast
cancer patients, but unlike other HRQL domains,
they are less likely to improve over time [9, 24, 38].
It is possible that differences between WHEL and
WHI-DM participants in domains such as arm
pain, sexual functioning, body image, or fear of
recurrence may be statistically significant and
meaningful.
It has been suggested that a difference of 5
points between a group mean and a fixed norm,
such as a general population norm, is ‘clinically
and socially relevant’ ([3], p. 7:12). Wywrich et al.
identified meaningful intra-individual differences
for SF-36 scales based on one standard error of
measurement [39]. They reported a range of
meaningful differences from 7.7 points for the
physical functioning scale to 14.2 points for the
social functioning scale [39]. We observed a group
difference in the role-physical scale of 5.3 points
(see Table 2) that we concluded was clearly not
meaningful due to small effect sizes (0.12–0.19).
Similarly, a score difference as large as 9.8 points
for the social functioning scale was deemed only
potentially meaningful (effect sizes 0.35–0.47). Our
results and those of Wywrich et al. suggest that the
variability across SF-36 scales may simply be too
great to rely on a single number for interpreting
score differences.
We used two sources of SDs to calculate effect
sizes; the RMSE from the ANCOVA models and
normative data. For most SF-36 scales, the RMSE
tended to fall in the center or towards the low end
of the range of norm SDs. Because the magnitude
of a meaningful difference may vary slightly across
patient groups, reporting a range rather than a
single number has been recommended [29, 40]. By
using two sources of SDs and computing a range
of plausible effect sizes, we have met this recom-
mendation.
Many of the statistically significant differenceswe
observed in SF-36 scores were associated with small
to moderate effect sizes and were considered only
potentially meaningful. In a recent study of HRQL
in theWHIHormoneReplacement Therapy (WHI-
HRT) trial, Hays et al. [19] compared RAND-36
scores between the estrogen plus progestin and the
placebo groups. They reported statistically signifi-
cant differences for physical functioning (0.8 points)
and bodily pain (1.9–2.0 points) scales, but con-
cluded these differences were not meaningful based
on the small effect sizes associated with them. As
with our study, Hays et al. [19] incorporated effect
sizes to aid in the interpretation of HRQL com-
parisons across groups.
Effect sizes for the WHEL vs. MOS or the WHI-
DM vs. MOS score differences were larger and
more likely to be clearly meaningful for scales
more strongly associated with the physical health
domain, (namely physical function, role-physical,
general health and the PCS) than for scales more
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strongly associated with the mental health domain
(namely vitality, social functioning, mental health
and the MCS). By incorporating effect sizes we
were able to detect a pattern not readily apparent
by comparing the magnitude of unadjusted scores
(Figure 1) or the magnitude of adjusted scale score
differences (Table 2). That we observed larger
differences in the physical health domain of these
samples is understandable given that three of the
four conditions present in the MOS participants
were physical (hypertension, diabetes, and heart
disease). Comorbid conditions, such as those
experienced by the MOS sample, have been shown
to be related to decreased HRQL [3, 23, 41].
WHEL and WHI-DM women were self-selected
to participate in dietary intervention trials, and
therefore, were likely to have better overall health
status, even though WHEL participants had been
diagnosed and treated for breast cancer within
the 4 years prior to enrollment. The WHEL and
WHI-DM protocols are somewhat demanding;
participants are highly functioning, and they are
motivated to adopt the dietary changes. These
characteristics may further explain why women in
the WHEL and WHI-DM samples had better
HRQL than the MOS sample.
Our study is not without limitations. We ex-
cluded participants due to missing SF-36 scale
data or demographic data. It is possible that par-
ticipants with missing data differ in their HRQL
from those with complete data; thus, excluding
participants with missing data may have intro-
duced selection bias. The random sample of the
420 WHI-DM participants was not representative
of sampling frame 0f 764 women from which it
was taken with respect to demographic charac-
teristics, and the random sample of 420 MOS
participants was not representative of its sampling
frame of 1741 participants with respect to mean
role-emotional and general health scales. To en-
sure these discrepancies did not markedly affect
the results, the analysis was repeated with the all
2925 participants with complete data from the
three studies (420 WHEL + 764 WHI-DM +
1741 MOS; data not shown). The results for the
large samples and the random samples were the
same for general health scale. The mean differences
for the role-emotional scale comparisons were
slightly smaller for the large samples and the effect
sizes were in the potentially meaningful range for
both the WHEL – MOS comparison (0.37–0.46)
and WHI-DM – MOS comparison (0.38–0.48)
rather than the clearly meaningful range (0.44–
0.56 and 0.44–0.55, respectively) for the random
samples. The overall conclusions, however, were
the same in that HRQL for the WHEL and WHI-
DM samples was better than that for the MOS,
particularly with respect to scales related to phys-
ical health.
The item measuring the severity of bodily pain
that was administered to the WHEL and WHI-
DM participants was missing the ‘very severe’
response option, and it could not be scored as in-
tended by the SF-36 scoring algorithms [3].
Although this error did not affect comparisons of
the bodily pain scale between the WHEL and
WHI-DM samples, it might have affected the
comparisons between these two samples and the
MOS sample and population norms; bodily pain
was the only scale that did not differ between the
MOS and the WHEL or WHI-DM samples.
Because women enrolled in WHEL and
WHI-DM were motivated and self-selected to
participate in these dietary intervention studies,
the results of the current study may not be gen-
eralizable to the general population, to breast
cancer survivors, or to other patient groups. Fur-
thermore, only participants at the UC Davis sites
of the WHEL and WHI-DM studies were included
in our study. As these are both multi-center stud-
ies, the results of our study may not reflect the
HRQL of the WHEL or WHI-DM participants in
general. Finally, WHEL and WHI-DM partici-
pants were from the same geographic area in
northern California, whereas MOS participants
were from Boston, Chicago, and Los Angeles,
which may account for some of the observed dif-
ferences in HRQL between MOS and either the
WHEL or WHI-DM.
We conclude that the HRQL of the healthy
postmenopausal women and breast cancer survi-
vors was similar, whereas both of these groups had
better HRQL than women with chronic health
conditions. Statistically significant group differ-
ences between women with chronic health condi-
tions and either breast cancer survivors or healthy
women were more likely to be clearly meaningful
(i.e., effect sizes greater than 0.5) for the physical
health domain of HRQL as measured by the
SF-36 (e.g., physical functioning, role-physical,
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general health, PCS) than for the mental health
domain (e.g., vitality, social functioning, mental
health, MCS), a pattern that may not have been
detected without the aid of effect sizes. This study
illustrated the use of internal (RMSE) and external
(U.S. population norms for females) sources of
SDs for deriving ranges of effect sizes to aid the
interpretation of multiple group comparisons.
These results should be useful to investigators
interested in estimating and interpreting SF-36
score differences across independent studies.
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